W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza II/III
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI…
Miasta: Bydgoszcz, Gdynia, Lublin, PoznańWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II/III
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast…
Miasta: Biała Podlaska, Opole, Skórzewo, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza II
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer…
Miasta: Prabuty, WieliszewWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company